<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02177955</url>
  </required_header>
  <id_info>
    <org_study_id>001.0.097.000-08</org_study_id>
    <secondary_id>001.0.097.000-08</secondary_id>
    <nct_id>NCT02177955</nct_id>
  </id_info>
  <brief_title>Comparative Study of Hemodynamic Changes Caused by Diazepam and Midazolam During Third Molar Surgery</brief_title>
  <official_title>Comparative Study of Hemodynamic Changes Caused by Diazepam and Midazolam During Third Molar Surgery. A Prospective Randomized Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jimmy Barbalho</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Pernambuco</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pernambuco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objective: The aim of the present study was to compare hemodynamic changes using 7.5 mg of
      midazolam and 10.0 mg of diazepam during the surgical removal of symmetrically positioned
      third molars.

      Study design: A prospective, randomized, double-blind, clinical trial was carried out
      involving 120 patients divided in three groups: Group 1 (diazepam and placebo), Group 2
      (midazolam and placebo) and Group 3 (diazepam and midazolam). Each subject underwent two
      surgeries on separate occasions under local anesthesia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study design A double-blind, randomized, crossover, clinical trial with a split-mouth design
      was carried out. This study received approval from the Human Research Ethics Committee of the
      institution at which it was carried out (process number: 001.0.097.000-08) and was conducted
      in compliance with the Consolidated Standards of Reporting Trials (CONSORT) statement. All
      patients signed a statement of informed consent agreeing to participate in the study.

      Sample size and pilot study The sample size was estimated using the a computational program.
      Thirty patients were submitted to third molar surgeries in a pilot study to determine the
      sample size. This step was necessary due to the lack of similar studies in the literature.
      Calculations were performed with specific programs taking into consideration the variables, a
      95% confidence interval, 80% test power and 5% error. At the end of the study, 120 patients
      were analyzed (40 in each group), totaling 240 surgeries.

      Sample selection One hundred twenty eight individuals between 18 and 40 years of age were
      selected for participation in the present study and submission to maxillary and mandibular
      third molar extractions bilaterally at the Department of Oral-Maxillofacial Surgery. Each
      patient was to be submitted to two surgeries. The third molars (maxillary or mandibular)
      needed to have the same degree of impaction on both sides.

      Three groups were formed: Group A received diazepam and placebo, Group B received midazolam
      and placebo and Group C received midazolam and diazepam. For the purposes of randomization
      and blinding of the surgeon and researcher in charge of analyzing the results, the groups
      were renominated Groups 1, 2 and 3. The randomization procedure was carried out by a
      researcher who was not directly involved in the surgeries or evaluations. Sequentially
      numbered, sealed, opaque envelopes were used, each containing a combination of substances and
      the side to be submitted to the first surgery. For each patient, the researcher opened an
      envelope, informed the main investigator and surgeon of the side to be operated, and
      administered the substance to the patient. The second surgery was performed on the
      contralateral side with the administration of the second substance. Blinding was performed to
      avoid awareness regarding what substance was administered in each surgery. For such, the
      pills were fabricated with the same outer color and a standardized size at the Pernambuco
      Pharmaceutical Laboratory (Brazil) and were packaged in recipients with the same color. The
      recipients were denominated 1, 2 and 3.

      Surgical procedures and medications As the patients were classified as healthy, no
      prophylactic use of antibiotics was performed prior to surgery for the prevention of
      bacterial endocarditis, as recommended by the American Heart Association. All patients rinsed
      their mouths with 0.12% chlorhexidine for one minute prior to surgery to reduce the bacterial
      population in the oral cavity. Moreover, all patients were instructed to take two 4-mg pills
      of dexamethasone one hour prior to surgery. The use of a corticosteroid in the preoperative
      period minimizes the occurrence of postoperative swelling and reduces the risk of trismus.13
      The substances (diazepam, midazolam and placebo) were administered orally 45 minutes prior to
      the surgical procedure. As the substances were masked, neither the surgeon nor the patient
      was aware of what substance was given (double-blind study).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes from baseline in systolic blood pressure until the end of surgery</measure>
    <time_frame>baseline, 2 minutes, 7 minutes, 12 minutes, end of surgery.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes from baseline in diastolic blood pressure until the end of surgery</measure>
    <time_frame>Baseline, 2 minutes, 7 minutes, 12 minutes, end of surgery</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes from baseline in mean blood pressure until the end of surgery</measure>
    <time_frame>Baseline, 2 minutes, 7 minutes, 12 minutes, end of surgery</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes from baseline in heart rate until the end of surgery</measure>
    <time_frame>Baseline, 2 minutes, 7 minutes, 12 minutes, end of surgery</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes from baseline in rate pressure product until the end of surgery</measure>
    <time_frame>Baseline, 2 minutes, 7 minutes, 12 minutes, end of surgery</time_frame>
    <description>The rate pressure is the product of the multiplication of systolic blood pressure by heart rate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes from baseline in oxygen saturation until the end of surgery</measure>
    <time_frame>Baseline, 2 minutes, 7 minutes, 12 minutes, end of surgery</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in pressure rate quotient until the end of surgery</measure>
    <time_frame>Baseline, 2 minutes, 7 minutes, 12 minutes, end of surgery</time_frame>
    <description>Pressure rate quotient is calculated by dividing mean blood pressure by heart rate</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Anxiety</condition>
  <arm_group>
    <arm_group_label>midazolan</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>7.5 mg midazolan 45 minutes before the surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>diazepam</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>10 mg diazepam 45 minutes before the surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>7.5 mg Midazolam</intervention_name>
    <description>7.5 mg midazolam 45 minutes before surgery</description>
    <arm_group_label>midazolan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>10 mg diazepam</intervention_name>
    <description>10 mg midazolam 45 minutes before surgery</description>
    <arm_group_label>diazepam</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The inclusion criteria were classification in Group 1 of the American Society of
             Anesthesiology (normal healthy patient with no adverse systemic condition or
             continuous use of medication) and no self-reported reactions or allergies to the drugs
             employed in the study

        Exclusion Criteria:

          -  The exclusion criteria were refusal to participate after reading the statement of
             informed consent, self-reported allergy to the drugs employed and failure to return
             for the second surgery on the contralateral side
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>HÃ©cio H De Morais, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pernambuco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>School of Dentistry of Pernambuco</name>
      <address>
        <city>Recife</city>
        <state>Pernambuco</state>
        <zip>54756220</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 21, 2014</study_first_submitted>
  <study_first_submitted_qc>June 26, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2014</study_first_posted>
  <last_update_submitted>June 26, 2014</last_update_submitted>
  <last_update_submitted_qc>June 26, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 30, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Pernambuco</investigator_affiliation>
    <investigator_full_name>Jimmy Barbalho</investigator_full_name>
    <investigator_title>DDs</investigator_title>
  </responsible_party>
  <keyword>Third Molar</keyword>
  <keyword>Anty-anxiety drugs</keyword>
  <keyword>hemodynamic</keyword>
  <keyword>Benzodiazepines</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midazolam</mesh_term>
    <mesh_term>Diazepam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

